RxSight, Inc. (RXST) Guidance & Earnings Results

On 2026-08-05 RxSight, Inc. lowered guidance: "Withdrew 2026 guidance; will resume formal guidance in early…" — from its own filing, as read by EquiReason.

Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason

RXSTRxSight, Inc.Follow RXST — free

Medical Devices · Healthcare

—

Price chart with a free account

Market cap: 208.8M
P/E TTM: —
Dividend yield: —
52-week: —
Next earnings: 3 Nov, in 10 days

What management guided

each earnings 8-K · figures checked against the filing text

Release	Direction	What they said
5 Aug 26	Lowered	Withdrew 2026 guidance; will resume formal guidance in early 2027. · full year
6 Jul 26	Lowered	Sales guidance cut from $120-135M to $110-120M; gross margin raised from 70-72% to 73-75% · full year
6 May 26	Reaffirmed	Revenue $120-135M; gross margin 70-72%; op ex $150-160M (high end) · full year
25 Feb 26	Lowered	FY2026 revenue guidance $120-135M vs FY2025 actual $134.5M; gross margin 70-72% vs 76.6%
12 Jan 26	Raised	FY2025 revenue guidance raised from $125-130M to $134.5M · full year
5 Nov 25	Mixed	FY2025 revenue $125-130M (narrowed); gross margin 76-77% (raised); opex $145-155M (reiterated) · full year
7 Aug 25	Reaffirmed	FY2025 revenue $120.0M-$130.0M; gross margin 72%-74%; operating expenses $145.0M-$155.0M; non-cash stock-based compensation $27.0M-$30.0M · full year

RxSight, Inc. — questions

What guidance did RxSight, Inc. give?: On 2026-08-05: "Withdrew 2026 guidance; will resume formal guidance in early 2027."
When does RxSight, Inc. report earnings?: RxSight, Inc.'s next earnings report is expected on 2026-11-03.

Every figure on this page comes from RxSight, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.

How these figures are read: methodology · EquiReason.

Important information. Figures on this page are taken from filings submitted to the U.S. Securities and Exchange Commission (SEC) and processed automatically by EquiReason. They may contain errors, omissions or delays, and EquiReason makes no representation or warranty as to their accuracy, completeness or timeliness. Always verify figures against the original filing on SEC EDGAR before relying on them.

This page is provided for general information and educational purposes only. It does not constitute investment, financial, legal or tax advice, and it is not a recommendation or an offer to buy, sell or hold any security. It does not take into account your objectives, financial situation or needs. Past performance does not guarantee future results; any reliance on this information is at your own risk. See our Disclaimer and Risk Disclosure.